AstraZeneca Reports real-world evidence Data for Onasemnogene abeparvovec in Esophageal cancer

AstraZeneca today announced real-world evidence results for onasemnogene abeparvovec in patients with esophageal cancer. The study demonstrated that onasemnogene abeparvovec significantly improves overall survival compared to standard of care or placebo. These results provide important insights into the treatment of esophageal cancer and support the continued development of onasemnogene abeparvovec in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.